Free Trial

Wells Fargo & Company's Rating of Ionis Pharmaceuticals on 7/30/2026

On July 30, 2026, Wells Fargo & Company updated its outlook on Ionis Pharmaceuticals (NASDAQ:IONS) with the action "Lower Price Target", setting a price target of $95.00. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Wells Fargo & Company

DateCompanyAction
10/16/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Boost Price Target
10/16/2026
Eastman Chemical Company stock logo
EMN
Eastman Chemical
Set Price Target
10/16/2026
Ashland Inc. stock logo
ASH
Ashland
Set Price Target
10/16/2026
Smith Douglas Homes Corp. stock logo
SDHC
Smith Douglas Homes
Lower Price Target
10/16/2026
KB Home stock logo
KBH
KB Home
Lower Price Target
10/16/2026
D.R. Horton, Inc. stock logo
DHI
D.R. Horton
Lower Price Target
More Ratings From Wells Fargo & Company